CooperCompanies Q3 rev up 6% YoY to $1.06 bln, EPS down 6% to $0.49.

• CooperCompanies Q3 revenue up 6% YoY to $1,060.3 million • CooperVision revenue up 6% to $718.4 million • CooperSurgical revenue up 4% to $341.9 million • GAAP diluted EPS down 6% to $0.49 • Non-GAAP diluted EPS up 15% to $1.10

CooperCompanies (Nasdaq: COO), a leading global medical device company, reported its third-quarter (Q3) 2025 financial results, highlighting a 6% year-over-year (YoY) increase in revenue to $1,060.3 million. The company's CooperVision segment saw a 6% increase in revenue to $718.4 million, while CooperSurgical's revenue rose 4% to $341.9 million. Despite these gains, GAAP diluted earnings per share (EPS) decreased by 6% to $0.49, while non-GAAP diluted EPS surged 15% to $1.10.

The company attributed its operational success to robust margins and strong free cash flow of $164.6 million. CooperCompanies also repurchased $52.1 million of common stock at an average price of $71.97 during Q3. Management updated its fiscal 2025 guidance, projecting total revenue of $4,076-$4,096 million with organic growth of 4-4.5%, and non-GAAP diluted EPS of $4.08-$4.12.

CooperVision, which accounted for 68% of the company's revenue, grew 6% reported but only 2% organically. Regional performance varied significantly, with EMEA leading at 6% organic growth, while Americas and Asia Pacific saw 3% and 5% organic declines, respectively. CooperSurgical, making up 32% of revenue, grew 4% reported and 2% organically, with the fertility business outperforming at 3% organic growth.

Despite revenue growth below expectations, CooperCompanies raised its earnings guidance, projecting improved revenue in Q4 and fiscal 2026, driven by its MyDAY® product line. The company's focus on profitability and operational excellence suggests confidence in navigating a challenging revenue environment.

References:
[1] https://www.stocktitan.net/news/COO/cooper-companies-announces-third-quarter-2025-wsk1lyw535wb.html